Y.S.P. Southeast Asia Holding (7178) Fair Value & Analysis
Healthcare · MY · Market cap 295M MYR
Fair value as of: Jun 25, 2026
Analysis
Y.S.P. Southeast Asia Holding (7178) currently trades at 2.09 MYR, while our model-based Fair Value estimate is 3.88 MYR — implying the stock looks roughly 85.6% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Y.S.P. Southeast Asia Holding Berhad, together with its subsidiaries, engages in the manufacturing and trading of generic drugs in Malaysia, Singapore, Vietnam, Philippines, Cambodia, Myanmar, Brunei, Indonesia, Thailand, Africa, and internationally. It operates through three segments: Manufacturing, Trading, and Investment Holding. The company manufactures, sells, imports, exports, trades in, and distributes pharmaceutical and veterinary products, pharmaceutical fine chemicals, raw material, health food products, and medical devices. It also manufactures aquatic, cosmetic, and biotechnology and health products, as well as traditional herbal medicines, food and health supplements, and over-the-counter products; and offers management services. Y.S.P. Southeast Asia Holding Berhad was founded in 1987 and is headquartered in Kuala Lumpur, Malaysia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Y.S.P. Southeast Asia Holding (7178) undervalued?
What is the fair value of 7178?
What is the quality score of 7178?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.